Antibody levels to multiple malaria vaccine candidate antigens in relation to clinical malaria episodes in children in the Kasena-Nankana district of Northern Ghana

Malaria Journal

Volumn 10, Issue , 2011, Pages

  Dodoo, Daniel ^a   Atuguba, Frank ^b   Bosomprah, Samuel ^c   Ansah, Nana Akosua ^b   Ansah, Patrick ^b   Lamptey, Helena ^a   Egyir, Beverly ^a   Oduro, Abraham R ^b   Gyan, Ben ^a   Hodgson, Abraham ^b   Koram, Kwadwo A ^a  

^a University of Ghana   (Ghana)

^b NAVRONGO HEALTH RESEARCH CENTRE   (Ghana)

^c UNIVERSITY OF GHANA   (Ghana)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; IMMUNOGLOBULIN G; MALARIA VACCINE; PYRIMETHAMINE PLUS SULFADOXINE; PARASITE ANTIGEN; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY; RECOMBINANT PROTEIN;

ANTIBODY BLOOD LEVEL; ANTIGEN SPECIFICITY; ARTICLE; ASSAY; AXILLA TEMPERATURE; CHILD; GHANA; GROWTH INHIBITION; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALARIA; MORBIDITY; PARASITE; PARASITEMIA; POPULATION; RISK ASSESSMENT; AGE; BLOOD; FEASIBILITY STUDY; IMMUNOLOGY; INFANT; MALARIA FALCIPARUM; PARASITOLOGY; PATHOGENICITY; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; REGRESSION ANALYSIS; RISK FACTOR; STATISTICAL MODEL;

AGE FACTORS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CHILD; CHILD, PRESCHOOL; FEASIBILITY STUDIES; GHANA; HUMANS; IMMUNOGLOBULIN G; INFANT; LONGITUDINAL STUDIES; MALARIA VACCINES; MALARIA, FALCIPARUM; MODELS, STATISTICAL; PARASITEMIA; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; REGRESSION ANALYSIS; RISK FACTORS;

EID: 79955402715     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-10-108     Document Type: Article

References (35)

1. The malaria Atlas Project: developing global maps of malaria risk. SI Hay RW Snow, PLoS Med 2006 3 473 10.1371/journal.pmed.0030473 17147467
2. Immunological processes in malaria pathogenesis. L Schofield GE Grau, Nat Rev Immunol 2005 5 722 735 10.1038/nri1686 16138104 (Pubitemid 43086173)
3. Gamma-globulin and acquired immunity to human malaria. S Cohen IA Mcgregor S Carrington, Nature 1961 192 733 737 10.1038/192733a0 13880318
4. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. A Sabchareon T Burnouf D Ouattara P Attanath H Bouharoun-Tayoun P Chantavanich C Foucault T Chongsuphajaisiddhi P Druilhe, Am J Trop Med Hyg 1991 45 297 308 1928564
5. Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. SD Polley T Mwangi CH Kocken AW Thomas S Dutta DE Lanar E Remarque A Ross TN Williams G Mwambingu B Lowe DJ Conway K Marsh, Vaccine 2004 23 718 728 10.1016/j.vaccine.2004.05.031 15542195 (Pubitemid 39473204)
6. The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro. M Theisen S Soe C Oeuvray AW Thomas J Vuust S Danielsen S Jepsen P Druilhe, Infect Immun 1998 66 11 17 9423833 (Pubitemid 28018795)
7. The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria. D Courtin M Oesterholt H Huismans K Kusi J Milet C Badaut O Gaye W Roeffen EJ Remarque R Sauerwein A Garcia AJ Luty, PLoS One 2009 4 7590 10.1371/journal. pone.0007590 19859562
8. Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children. D Dodoo A Aikins KA Kusi H Lamptey E Remarque P Milligan S Bosomprah R Chilengi YD Osei BD Akanmori M Theisen, Malar J 2008 7 142 10.1186/1475-2875-7-142 18664257
9. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. FH Osier G Fegan SD Polley L Murungi F Verra KK Tetteh B Lowe T Mwangi PC Bull AW Thomas DR Cavanagh JS McBride DE Lanar MJ Mackinnon DJ Conway K Marsh, Infect Immun 2008 76 2240 2248 10.1128/IAI.01585-07 18316390 (Pubitemid 351656161)
10. Clinical features and pathogenesis of severe malaria. CL Mackintosh JG Beeson K Marsh, Trends Parasitol 2004 20 597 603 10.1016/j.pt.2004.09.006 15522670 (Pubitemid 39446751)
11. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. FJ Fowkes JS Richards JA Simpson JG Beeson, PLoS Med 2010 7 1000218 10.1371/journal.pmed. 1000218 20098724
12. Analysis of human antibodies to erythrocyte binding antigen 175 of Plasmodium falciparum. DM Okenu EM Riley QD Bickle PU Agomo A Barbosa JR Daugherty DE Lanar DJ Conway, Infect Immun 2000 68 5559 5566 10.1128/IAI.68.10.5559-5566.2000 10992454
13. Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. C Oeuvray M Theisen C Rogier JF Trape S Jepsen P Druilhe, Infect Immun 2000 68 2617 2620 10.1128/IAI.68.5.2617-2620.2000 10768952 (Pubitemid 30253834)
14. Multiplex assay for simultaneous measurement of antibodies to multiple Plasmodium falciparum antigens. GG Fouda RF Leke C Long P Druilhe A Zhou DW Taylor AH Johnson, Clin Vaccine Immunol 2006 13 1307 1313 10.1128/CVI.00183-06 17035513 (Pubitemid 46086895)
15. HLA-DRB1*04 allele is associated with severe malaria in northern Ghana. AD Osafo-Addo KA Koram AR Oduro M Wilson A Hodgson WO Rogers, Am J Trop Med Hyg 2008 78 251 255 18256425 (Pubitemid 351844560)
16. Antigenicity and immunogenicity of recombinant glutamate-rich protein of Plasmodium falciparum expressed in Escherichia coli. M Theisen J Vuust A Gottschau S Jepsen B Hogh, Clin Diagn Lab Immunol 1995 2 30 34 7719909
17. Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria. E Malkin CA Long AW Stowers L Zou S Singh NJ MacDonald DL Narum AP Miles AC Orcutt O Muratova SE Moretz H Zhou A Diouf M Fay E Tierney P Leese S Mahanty LH Miller A Saul LB Martin, PLoS Clin Trials 2007 2 12 10.1371/journal.pctr.0020012 17415408
18. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. M Roestenberg E Remarque E de Jonge R Hermsen H Blythman O Leroy E Imoukhuede S Jepsen O Ofori-Anyinam B Faber CH Kocken M Arnold V Walraven K Teelen W Roeffen Q de Mast WR Ballou J Cohen MC Dubois S Ascarateil d van A Thomas R Sauerwein, PLoS One 2008 3 3960 10.1371/journal.pone.0003960 19093004
19. Clinical case definitions and malaria vaccine efficacy. WO Rogers F Atuguba AR Oduro A Hodgson KA Koram, J Infect Dis 2006 193 467 473 10.1086/499314 16388497 (Pubitemid 43122349)
20. Parasite threshold associated with clinical malaria in areas of different transmission intensities in north eastern Tanzania. BP Mmbando JP Lusingu LS Vestergaard MM Lemnge TG Theander TH Scheike, BMC Med Res Methodol 2009 9 75 10.1186/1471-2288-9-75 19909523
21. Attributable fraction estimates and case definitions for malaria in endemic areas. T Smith JA Schellenberg R Hayes, Stat Med 1994 13 2345 2358 10.1002/sim.4780132206 7855468 (Pubitemid 24354857)
22. Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria. D Dodoo TG Theander JA Kurtzhals K Koram E Riley BD Akanmori FK Nkrumah L Hviid, Infect Immun 1999 67 2131 2137 10225865 (Pubitemid 29200463)
23. Severe anemia in young children after high and low malaria transmission seasons in the Kassena-Nankana district of northern Ghana. KA Koram S Owusu-Agyei G Utz FN Binka JK Baird SL Hoffman FK Nkrumah, Am J Trop Med Hyg 2000 62 670 674 11304052 (Pubitemid 32281483)
24. Seasonal profiles of malaria infection, anaemia, and bednet use among age groups and communities in northern Ghana. KA Koram S Owusu-Agyei DJ Fryauff F Anto F Atuguba A Hodgson SL Hoffman FK Nkrumah, Trop Med Int Health 2003 8 793 802 10.1046/j.1365-3156.2003.01092.x 12950665 (Pubitemid 37108479)
25. Malaria-induced acquisition of antibodies to Plasmodium falciparum variant surface antigens. MF Ofori D Dodoo T Staalsoe JA Kurtzhals K Koram TG Theander BD Akanmori L Hviid, Infect Immun 2002 70 2982 2988 10.1128/IAI.70.6.2982-2988.2002 12010988 (Pubitemid 34564157)
26. Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. I Nebie A Diarra A Ouedraogo I Soulama EC Bougouma AB Tiono AT Konate R Chilengi M Theisen D Dodoo E Remarque S Bosomprah P Milligan SB Sirima, Infect Immun 2008 76 759 766 10.1128/IAI.01147-07 18070896 (Pubitemid 351251748)
27. Antibody responses to repetitive epitopes of the circumsporozoite protein, liver stage antigen-1, and merozoite surface protein-2 in infants residing in a Plasmodium falciparum-hyperendemic area of western Kenya. XIII. Asembo Bay Cohort Project. Z Zhou L Xiao OH Branch S Kariuki BL Nahlen AA Lal, Am J Trop Med Hyg 2002 66 7 12 12135271 (Pubitemid 34733146)
28. Lymphocyte proliferation and antibody responses to Plasmodium falciparum liver-stage antigen-1 in a highland area of Kenya with seasonal variation in malaria transmission. CC John JH Ouma PO Sumba MR Hollingdale JW Kazura CL King, Am J Trop Med Hyg 2002 66 372 378 12164290 (Pubitemid 34810489)
29. Measurement of antibody levels against region II of the erythrocyte-binding antigen 175 of Plasmodium falciparum in an area of malaria holoendemicity in western Kenya. EA Ohas JH Adams JN Waitumbi AS Orago A Barbosa DE Lanar JA Stoute, Infect Immun 2004 72 735 741 10.1128/IAI.72.2.735-741.2004 14742515 (Pubitemid 38166650)
30. Differential antibody responses to Plasmodium falciparum glycosylphosphatidylinositol anchors in patients with cerebral and mild malaria. R Perraut B Diatta L Marrama O Garraud R Jambou S Longacre G Krishnegowda A Dieye DC Gowda, Microbes Infect 2005 7 682 687 15848275 (Pubitemid 40720423)
31. Parasite antigen-specific interleukin-10 and antibody reponses predict accelerated parasite clearance in Plasmodium falciparum malaria. AJ Luty B Lell R Schmidt-Ott LG Lehman D Luckner B Greve P Matousek K Herbich D Schmid S Ulbert F Migot-Nabias B Dubois P Deloron PG Kremsner, Eur Cytokine Netw 1998 9 639 646 9889408 (Pubitemid 29033931)
32. Immune response to Plasmodium falciparum liver stage antigen-1: geographical variations within Central Africa and their relationship with protection from clinical malaria. F Migot-Nabias P Deloron P Ringwald B Dubois J Mayombo TN Minh N Fievet P Millet A Luty, Trans R Soc Trop Med Hyg 2000 94 557 562 10.1016/S0035-9203(00)90086-5 11132389
33. Antibodies to the Plasmodium falciparum antigens circumsporozoite protein, thrombospondin-related adhesive protein, and liver-stage antigen 1 vary by ages of subjects and by season in a highland area of Kenya. CC John JS Zickafoose PO Sumba CL King JW Kazura, Infect Immun 2003 71 4320 4325 10.1128/IAI.71.8.4320-4325.2003 12874308 (Pubitemid 36919895)
34. Interleukin-10 responses to liver-stage antigen 1 predict human resistance to Plasmodium falciparum. JD Kurtis DE Lanar M Opollo PE Duffy, Infect Immun 1999 67 3424 3429 10377122 (Pubitemid 29291512)
35. Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine. JD Kurtis MR Hollingdale AJ Luty DE Lanar U Krzych PE Duffy, Trends Parasitol 2001 17 219 223 10.1016/S0169-4758(00)01862-7 11323304 (Pubitemid 32422165)